Albert Bourla, the Chairman and CEO of Pfizer Inc., has reported the acquisition of 71 phantom stock units, as detailed in a recent SEC filing. This transaction, valued at $28.37 per unit, highlights Bourla's ongoing commitment to the pharmaceutical giant.
The filing, dated October 14, 2026, indicates that the acquisition occurred on October 13, 2026. The move comes as part of Bourla's participation in Pfizer's Nonfunded Deferred Compensation and Supplemental Savings Plan, which allows for cash settlement following his separation from the company.
Background
Pfizer Inc. is a leading player in the pharmaceutical preparations sector, classified under the SIC code 2834. The company, incorporated in Delaware, has been a prominent name in the life sciences industry, focusing on innovative healthcare solutions. Recent filings show a consistent pattern of executive transactions, reflecting the dynamics of corporate governance within the company.
What the Filing Says
According to the filing, Bourla's recent transaction involved:
"71 phantom stock units acquired at a price of $28.37 each."
This acquisition increases Bourla's total ownership to 783,981 shares following the transaction.
Impact
This transaction may affect various stakeholders, including investors, employees, and competitors. Bourla's acquisition of phantom stock units indicates a strong alignment with the company's performance and future prospects, which may bolster investor confidence. Other pharmaceutical companies may also take note of how executive compensation structures are evolving in response to market conditions.
What's Next
The filing does not say what happens next.